- 专利标题： COMBINED PHARMACEUTICAL COMPOSITION OF C-MET KINASE INHIBITOR AND ANTI-PD-L1 ANTIBODY
-
申请号： US17999028申请日： 2021-06-01
-
公开(公告)号： US20230263795A1公开(公告)日： 2023-08-24
- 发明人: Xiquan ZHANG , Xunqiang Wang , Ding Yu , Tao LIU , Xiaole ZHAN , Naiying WU
- 申请人： CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. , TIANJIN MEDICAL UNIVERSITY CANCER INSTITUTE AND HOSPITAL
- 申请人地址： CN Lianyungang
- 专利权人： CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD.,TIANJIN MEDICAL UNIVERSITY CANCER INSTITUTE AND HOSPITAL
- 当前专利权人： CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD.,TIANJIN MEDICAL UNIVERSITY CANCER INSTITUTE AND HOSPITAL
- 当前专利权人地址： CN Lianyungang
- 优先权： CN 2010489236.1 2020.06.02 CN 2010489252.0 2020.06.02
- 国际申请： PCT/CN2021/097776 2021.06.01
- 进入国家日期： 2022-11-16
- 主分类号： A61K31/47
- IPC分类号： A61K31/47 ; A61K39/395 ; A61P35/00
摘要：
Provided are a combined pharmaceutical composition of an anti-PD-L1 antibody and a c-Met kinase inhibitor, specifically, a combined pharmaceutical composition of an anti-PD-L1 antibody and N-(4-((7-((1-(cyclopentylamino)cyclopropyl)methoxy)-6-methoxyquinolin-4-yl)oxy)-3-fluorophenyl)-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and the use of the combined pharmaceutical composition in the treatment of cancers, in particular, gastric cancer or liver cancer.
信息查询
